Background: Patients on dialysis sustain at least a threefold higher in-hospital mortality rate and markedly higher long-term mortality following coronary artery bypass graft surgery than the general population. Smaller studies have suggested that dialysis patients have superior outcomes with off-pump compared with on-pump coronary artery bypass surgery.
Patients with chronic kidney disease (CKD) are at markedly high risk for cardiovascular morbidity and mortality. Estimated glomerular filtration rate is strongly, inversely, and independently related to all-cause mortality, cardiovascular events, and rates of hospitalization. 1 Patients with CKD who have percutaneous and surgical coronary revascularization sustain markedly higher long-term all-cause mortality than patients without CKD. 2 One-year mortality for general Medicare patients without CKD who had coronary artery bypass graft (CABG) surgery in 2004 was 10% versus 22% for patients with CKD without end-stage renal disease (ESRD). 3 In comparison, 1-year mortality for patients on dialysis was 33%. 4 Thus, mortality risk increases as renal insufficiency worsens.
Off-pump coronary artery bypass (OPCAB) surgery is potentially attractive for patients likely to have severe vasculopathy, such as patients with ESRD. Its principal physiologic advantages over on-pump CABG surgery include the ability to avoid the deleterious consequences of the systemic inflammatory response incited by the bypass circuit 5 and atheroembolism caused by aortic cannulation and crossclamping. 6 Unfortunately, available literature regarding translating these physiologic advantages into improved clinical outcomes has been contradictory. The mortality benefit with OPCAB noted in larger registry data 7, 8 has not been reproduced in smaller, randomized trials. 9, 10 In particular, no survival advantage with OPCAB has been shown for low-risk patients. 10 This inconsistency in the literature raises the question of whether high-risk patients may benefit from OPCAB but may have been underrepresented in previous studies. Indeed, some studies suggest greater benefit of OPCAB for high-risk patients, especially elderly patients or patients with diabetes, previous stroke, or severe vascular disease, and patients having repeat CABG. 7, 8, 11, 12 Abbreviations and Acronyms CABG ¼ coronary artery bypass graft CI
Patients on dialysis constitute a high-risk population, sustaining at least a threefold higher in-hospital mortality rate and higher rates of nonfatal complications after CABG than the general population. 13 Historically, patients on long-term dialysis have been modestly represented in studies comparing OPCAB and on-pump CABG. 7, 9, 12 Limited published data for patients on dialysis suggest superior outcomes with OPCAB. 14, 15 The objectives of this study were to compare survival for patients on dialysis having OP-CAB versus on-pump CABG and to determine predictors of survival for patients on dialysis having CABG.
METHODS

Database and Patients
Data for this study are from the United States Renal Data System (USRDS) database (n ¼ 1,910,161). The accuracy of these data has been previously validated. 16 Institutional review board approval was obtained. Patients on dialysis who had first CABG (International Classification of Diseases, Ninth Edition, Clinical Modification [ICD-9-CM] procedure code 36.1) between January 1, 2001, and December 31, 2006, after renal replacement therapy initiation, were identified for study inclusion. Those who had CABG without cardiopulmonary bypass (OPCAB) were further identified by Current Procedural Terminology (CPT) code 00566. To assess for possible crossover from the OPCAB to the on-pump CABG arm, CPT code 00562 (with pump oxygenator) was assessed during the hospitalization for OPCAB surgery. Internal thoracic graft use and number of vessels bypassed were identified by ICD-9-CM codes 36. 15, 36.16, and 36.11-36.19 .
All eligible patients had been diagnosed with ESRD at least 90 days before CABG, were aged ! 20 years on the date of surgery, and resided in the 50 US states, Washington DC, or the US territories. All patients had Medicare as primary payer. Patients having concomitant valve surgery or with prior CABG were excluded from the analysis.
Patient baseline characteristics included demographic factors (age, sex, race, ESRD duration, ESRD cause, dialysis modality, prior renal transplant), surgical variables (year of surgery, number of vessels bypassed, use of internal thoracic graft), length of hospital stay for the CABG surgery admission, and comorbid conditions. Comorbid conditions were determined from the Centers for Medicare & Medicaid (CMS) ESRD Medical Evidence Report (form CMS-2728) and Medicare claims using a previously published methodology 17, 18 and included acute myocardial infarction, congestive heart failure, other cardiac conditions, cerebrovascular accident/transient ischemic attack, diabetes, dysrhythmias, chronic obstructive pulmonary dis-ease, gastrointestinal bleeding, liver disease, cancer, and peripheral vascular disease.
The outcomes evaluated were all-cause mortality, a combined event of second CABG and all-cause mortality, and cardiac mortality. Cardiac mortality was determined using data derived from the ESRD Death Notification form (CMS-2746). Death ascribed to myocardial infarction, pericarditis (including cardiac tamponade), atherosclerotic heart disease, cardiomyopathy, cardiac arrhythmia, cardiac arrest (cause unknown), valvular heart disease, pulmonary edema due to exogenous fluid, and congestive heart failure were classified as being due to cardiac causes. 2 For all-cause and cardiac mortality, patients were followed from the date of CABG to the earliest occurrence of death, 3 years after first CABG, or December 31, 2006. For the combined event of second CABG and all-cause mortality, patients were followed to the earliest occurrence of second CABG, death, 3 years after first CABG, or December 31, 2006. Patients were censored at renal transplant or loss to follow-up.
Data Analysis
Baseline characteristics of the OPCAB and on-pump CABG study populations were defined as categorical variables and presented as proportions. Differences were tested using the chi-square test. Length of stay for the CABG surgery admission was also presented as a continuous variable, and the difference between the 2 study groups was tested using the 2-sample t test. In-hospital mortality was determined for both groups and the difference was tested using the chi-square test. Survival was estimated by the Kaplan-Meier method, and subgroup survival was compared by log-rank test. A Cox proportional hazards model was used to assess the effect of OP-CAB on mortality risk compared with on-pump CABG with adjustment for patient baseline characteristics. All statistical analyses were performed using SAS for Windows, version 9 (SAS Institute Inc, Cary, NC).
RESULTS
We identified 13,085 patients on dialysis (11,977 on hemodialysis and 1108 on peritoneal dialysis) who had CABG surgery during the study period. Of these, 2335 (17.8%) had OPCAB. For all-cause mortality, mean AE standard deviation follow-up time was 16.9 AE 13.0 months for patients having OPCAB and 17.1 AE 13.3 months for patients having on-pump CABG. Similar mean follow-up times were observed for the combined event of second CABG and allcause mortality: 16.7 AE 13.0 months for patients having OP-CAB and 17.0 AE 13.3 months for patients having on-pump CABG. The median follow-up time for death was 14.84 months for both groups. The median follow-up time for the combined event of death and second CABG was 14.57 months for patients having OPCAB and 14.61 months for patients having on-pump CABG.
Of the 2335 patients having OPCAB, 1050 (45.0%) died, 552 (23.6%) died of cardiac disease, 32 (1.4%) had a second CABG, and 4.4% were censored for renal transplant and 0.2% for loss to follow-up. Of the 10,750 patients having on-pump CABG, 4993 (46.5%) died, 2562 (23.8%) died of cardiac disease, 123 (1.1%) had a second CABG, and 5.6% were censored for renal transplant and 0.2% for loss to follow-up.
Patients having OPCAB were more likely than those having on-pump CABG to be older and to have peripheral vascular disease but not previous cerebrovascular accident/ transient ischemic attack (Table 1) . Patients having OPCAB were likely to have fewer coronary arteries bypassed than patients having on-pump CABG. Interestingly, although internal thoracic graft use was high in both groups, it was significantly higher for patients having OPCAB.
The number of patients having OPCAB increased progressively from 2001 to 2006, likely reflecting improved operator expertise, more published literature and increased awareness regarding OPCAB, and technological advances in the field including development of mechanical stabilization and cardiac positioning devices for OPCAB. The mean length of stay during the CABG surgery hospitalization was similar in both groups (15.32 days for OPCAB versus 15.73 days for on-pump CABG, P ¼ .17). The median length of stay was 12 days in both study groups.
In-hospital mortality was 9.7% for patients having OPCAB and 11.0% for patients having on-pump CABG (P ¼ .06). Figure 1 presents the Kaplan-Meier curves for all-cause survival for patients having OPCAB and patients having on-pump CABG. The observed benefit of OPCAB on all-cause survival was most notable in the first 12 months after surgery. The estimated all-cause survival rates for patients having OPCAB and patients having on-pump CABG, respectively, were 90.4% versus 88.5% (P ¼ .0087) at 30 days, 78.2% versus 76.5% (P ¼ .07) at 6 months, 70.3% versus 68.7% (P ¼ .10) at 1 year, 55.4% versus 55.2% at 2 years, and 42.1% versus 42.3% at 3 years. After adjustment for baseline patient characteristics, OPCAB was associated with an 8% reduction in death compared with on-pump CABG (hazard ratio, 0.92; 95% confidence interval [CI], 0.86-0.99; P ¼ .02).
When the combined event of second CABG and death was examined via Cox proportional hazards model, OPCAB continued to be associated with a statistically significant reduction in second CABG or death compared with on-pump CABG (hazard ratio, 0.92; 95% CI, 0.86-0.98; P ¼ .01). For the end point of second CABG alone, we found no difference between the 2 groups (P ¼ .22).
We also evaluated first claim for percutaneous coronary intervention (PCI) after the admission for CABG surgery. In the OPCAB group 103 patients (4.41%) and in the Advanced age, diabetic ESRD, dialysis duration, peritoneal dialysis, and cardiovascular comorbid conditions (congestive heart failure, myocardial infarction, and peripheral vascular disease) were identified as independent predictors of all-cause mortality ( Table 2) . Consistent with prior publications on coronary revascularization, survival was better for African-American patients on dialysis than for white patients on dialysis. 13 Interestingly, single-vessel CABG versus multivessel CABG was noted to be an independent predictor of mortality, perhaps reflecting incomplete revascularization. Concordant with prior data on CABG in the general population, use of internal thoracic grafts was associated with an 8% reduction in mortality (hazard ratio, 0.92; 95% CI, 0.87-0.98; P ¼ .0057).
The adjusted hazards ratio of cardiac mortality for OP-CAB versus on-pump CABG was 0.95 (95% CI, 0.86-1.04; P ¼ .26).The observed benefit of OPCAB on cardiac survival was most notable in the first 6 months after surgery and diminished after 12 months. The estimated cardiac survival rates for patients having OPCAB and patients having on-pump CABG, respectively, were 93.8% versus 92.4% (P ¼ .02) at 30 days, 87.6% versus 86.3% (P ¼ .09) at 6 months, 82.6% versus 82.2% at 1 year, 73.4% versus 74.2% at 2 years, and 64.1% versus 65.5% at 3 years.
Of the 2335 patients having OPCAB, 110 (4.7%) had claims with CPT code 00562 (with pump oxygenator) during the same hospitalization, suggesting crossover to an on-pump CABG procedure. The Kaplan-Meier survival estimates at 30 days for the crossover OPCAB group, the OP-CAB-only group, and the on-pump CABG group were 88.1%, 90.5%, and 88.5% respectively (P value by logrank test ¼ .024). The survival advantage for the OPCABonly group was lost at 6 months after the surgery.
DISCUSSION
Patients on dialysis constitute an extremely high-risk population with respect to outcomes following CABG surgery; Herzog and colleagues 13 previously reported in-hospital mortality of 8.6% and 2-year mortality of 44%. Using the Society of Thoracic Surgeons database, Cooper and associates 19 noted an operative mortality rate of 9% for dialysisdependent patients having CABG surgery, with a marked incremental increase in mortality with worsening glomerular filtration rates. Due to the possible benefit of OPCAB for high-risk populations, it is reasonable to evaluate its use in patients on dialysis as a potential strategy to reduce mortality associated with CABG. Manabe and coworkers 20 suggested a physiologic basis for supporting OPCAB in patients on hemodialysis by demonstrating improved cardiac hemodynamics in the form of postoperative reduction in right atrial and pulmonary capillary wedge pressure and improvement in postoperative lung oxygenation compared with patients having on-pump CABG.
We found an 8% risk reduction in all-cause mortality associated with OPCAB in patients on dialysis. This modest benefit was noted primarily in the first year after surgery, likely reflecting the advantages of the surgical technique itself in preventing deleterious inflammatory, vascular, and embolic consequences of cardiopulmonary bypass in various organ beds, 5, 6 combined with a postulated favorable early effect on cardiac hemodynamics. 20 Because patients on dialysis constitute an extremely high-risk population with regard to operative and long-term mortality, this benefit might be attenuated. The high rates of noncardiac mortality we noted point to the complex noncardiac morbidity in this population. This is further reflected by the longer hospital stays for patients on dialysis despite OPCAB use in this study, contrary to observations from previous studies in the general population.
Few studies have previously assessed the impact of OP-CAB on mortality in patients on dialysis. 14, 15, [21] [22] [23] Dewey and colleagues 14 studied 158 patients on hemodialysis; 37.3% had OPCAB. The authors reported a mortality benefit with OPCAB, but it should be noted that the perioperative mortality in their OPCAB group was extraordinarily low at 1.7% versus 17.2% for the on-pump CABG control group. Beckermann and associates 15 studied 3922 patients in the USRDS database; 13.8% had OPCAB in a 2-year entry period. The authors reported a 14% risk reduction in all-cause mortality for the OPCAB group compared with the on-pump CABG group, but the researchers did not assess the potentially important effect of number of vessels bypassed. Moreover, the sample size in the current study is approximately 3 times larger, with length-of-stay information and more recent patient data, compared with the study by Beckermann and colleagues. 15 OPCAB may also confer short-term benefit in the general population. Hannan and coworkers 24 reported a significant 19% reduction in inpatient and 30-day mortality using New York state registry data. In a meta-analysis of 14 non-randomized trials, Panesar and colleagues 25 showed a marked reduction in in-hospital mortality rates, especially among octogenarians. In another meta-analysis, Wijeysundera and colleagues 26 found a short-term mortality advantage in observational studies but not randomized studies.
Similar to our study, previous studies have demonstrated that the early benefit of OPCAB disappears in the long term. In a large retrospective study, Hannan and associates 24 found that 3-year mortality rates with OPCAB were comparable to on-pump CABG. Further, concerns have been raised regarding OPCAB and the long-term adequacy of revascularization. 24, 26, 27 We found no significant difference in occurrence of second CABG for OPCAB versus on-pump CABG. Reassuringly, we found no increase in mortality for patients having OPCAB in longer follow-up.
Only 17.8% of our study group had OPCAB over 6 years, less than the 25% to 30% OPCAB use in the general population in New York state. 24, 28 Although there has been a slight interval increase in the percentage of patients on dialysis who now have OPCAB (17.8% in the current study vs 14% in 2001-2002), 15 OPCAB is relatively underused in this high-risk patient population compared with the general population.
Our study has several limitations. The retrospective nature of the evaluation introduces the possibility of selection bias. The USRDS database consists predominantly of administrative data. Clinical variables such as left ventricular ejection fraction, functional class, coronary arteriographic data, and degree of aortic calcification could not be studied. Previous studies have reported a higher mortality rate following a crossover or conversion from OPCAB to an on-pump procedure. 29 Thus, we attempted to assess the number of patients who crossed over, but the method we used may have underestimated the crossover rate.
In summary, this study represents the largest number of patients on long-term dialysis for whom OPCAB and on-pump CABG outcomes have been compared. Our findings indicate that patients on dialysis are a high-risk population and sustain very high in-hospital and 2-year mortality rates. Patients on dialysis may benefit from OPCAB by reduced early mortality compared with on-pump CABG. Randomized controlled trials are needed in this high-risk patient population to ascertain the strength of this benefit. Based on our observational data, OPCAB for patients on dialysis who have CABG surgery may offer a modest benefit in outcome.
